Maker of Vioxx Subject of Grand Jury Probe
By Sophia Brink
Published on February 01, 2008
The Health Care Fraud division of the U.S. Attorney’s Office for the District of Massachusetts is handling the investigation.
Merck voluntarily recalled Vioxx from the market on Sept. 30, 2004, after a study showed a correlation between use of the drug and an increased risk of heart attack.
Facing over 26,000 separate lawsuits, Merck proposed a $4.85 billion settlement in November.
Attorney Joseph L. Doherty, of the Boston law firm Doherty & Quill, doesn’t believe that the investigation will affect plaintiffs’ decisions whether or not to accept the settlement.
Past federal drug marketing probes have led to multimillion dollar settlements. In October 2001, after a Department of Justice probe of TAP Pharmaceutical Products, which makes the prostate cancer drug Lupron, the company agreed to pay the federal government $875 million. AstraZeneca pleaded guilty to illegal marketing in 2003, agreeing to settle the charges against them for $355 million.
A spokesperson for Merck could not be reached for comment.
Keyword Tags: